Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kiniksa Pharmaceuticals Ltd (NQ: KNSA )

14.07 +0.30 (+2.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 328,606
Open 13.77
Bid (Size) 13.60 (1)
Ask (Size) 15.12 (1)
Prev. Close 13.77
Today's Range 13.50 - 14.30
52wk Range 7.360 - 17.20
Shares Outstanding 69,751,697
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A Look Into Healthcare Sector Value Stocks
 
Via Benzinga
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
Amid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own. 
Via InvestorPlace

Performance

YTD
-2.56%
-2.56%
1 Month
+28.14%
+28.14%
3 Month
+5.63%
+5.63%
6 Month
-11.17%
-11.17%
1 Year
+83.68%
+83.68%

More News

Read More
7 Small-Cap Stocks to Buy for Explosive Growth Potential
Via InvestorPlace
7 Dirt-Cheap Stocks Sitting in the Sweet Spot
Via InvestorPlace
The Top 7 Growth Stocks in Biotech
Via InvestorPlace
5 Value Stocks In The Healthcare Sector
Via Benzinga
Kiniksa Inks Global License Agreement With Roche For Vixarelimab
Via Benzinga
Recap: Kiniksa Pharmaceuticals Q1 Earnings
Via Benzinga
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Via Benzinga
Earnings Scheduled For February 22, 2022
Via Benzinga
Gartner, Sony, Uber And Other Big Gainers From Tuesday
Via Benzinga
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Recap: Kiniksa Pharmaceuticals Q3 Earnings
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Kiniksa Pharmaceuticals: Q2 Earnings Insights
Via Benzinga
Week In Review: Huadong Pharma Enters $662 Million Deal For Two Kiniksa Anti-Inflammatory Drugs
Via Talk Markets
Kiniksa Pharma, Huadong Medicine Ink Licensing Pact For Arcalyst, Mavrilimumab
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Kiniksa Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Via Benzinga
Why Kiniksa Pharmaceuticals Stock Is Falling Today
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
71 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Dow Rises Around 150 Points; Semler Scientific Shares Slide
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.